Form 8-K · Current Report · Filed 2025-06-23
Cidara Therapeutics Announces Positive Topline Results for CD388 in Phase 2b Trial
Cidara Therapeutics, Inc. announced on June 23, 2025, positive topline results from its randomized, double-blind, placebo-controlled Phase 2b NAVIGATE trial for CD388, an influenza prevention treatment. The study met its primary endpoint and all secondary endpoints, demonstrating statistically significant prevention efficacy across different dose groups. CD388 was well-tolerated with no unexpected adverse events. The company plans to present further results at scientific conferences and has requested an end-of-Phase 2 meeting with the FDA.
- Filer
- Cidara Therapeutics Inc. CDTX · NASDAQ
- Filed
- Accession
- 0001610618-25-000074
- CIK
- 0001610618
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$21.02
Next session
+122.8%
Since filing
+953.2%
Latest close
$221.38
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from CDTX reporting the same item, with the next session's move:
Exhibits (1)
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Never miss another CDTX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.